This presentation may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the safety, efficacy and regulato

March 2019 Targeting the biology of

aging to prevent and treat aging-related diseases Exhibit 99.1

This presentation may contain

"forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the safety, efficacy and regulatory and clinical progress of our product

candidates, including RTB101 alone and in combination with a rapalog, such as everolimus or sirolimus. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and

uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. The use of words such as "may," "might," "will,"

"should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or

"continue," and other similar expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs,

expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results and other future conditions. All statements other than statements of historical facts contained in this presentation, including

statements regarding future results of operations and financial position, business strategy, current and prospective product candidates, planned clinical trials and preclinical activities, including the initiation, timing, progress and results of

our preclinical and clinical studies and our research and development programs, product approvals, research and development costs, current and prospective collaborations, timing and likelihood of success, including our ability to advance RTB101

alone and in combination with everolimus or sirolimus into, and successfully complete, clinical studies, the timing and likelihood of success of our Phase 3 clinical trials of RTB101, and the timing or likelihood of regulatory filings and approvals,

expectations regarding market acceptance and size, plans for launch and commercialization, plans and objectives of management for future operations, and future results of anticipated product candidates, are forward-looking statements. New risks and

uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. These statements

are also subject to a number of material risks and uncertainties that are discussed in the section entitled "Risk Factors" in resTORbio's annual report on Form 10-K for the fiscal year ended December 31, 2017, as well as discussions

of potential risks, uncertainties, and other important factors in resTORbio's subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our

affiliates, advisors, or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. Certain information

contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While we believe these third-party sources to be

reliable as of the date of this presentation, we have not independently verified, and we make no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the

market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while we believe our own internal research is reliable, such

research has not been verified by any independent source. Forward-looking statements

resTORbio highlights First-in-class and

most advanced selective TORC1 program for aging-related diseases Extensive body of literature demonstrating that aging is a biology regulated by the TORC1 pathway Lead candidate, RTB101, is an orally administered, small molecule, potent TORC1

inhibitor product candidate Phase 3 program will evaluate whether RTB101 decreases, as compared to placebo, the percentage of subjects with clinical symptoms consistent with an RTI with or without laboratory-confirmation of a pathogen In two Phase 2

studies enrolling > 900 elderly subjects, RTB101 10mg QD was observed to improve immune function and reduce the incidence of RTIs Plan to initiate Phase 3 program in 2Q19; Data expected mid-2020 Data-driven approach to expand into potential

additional aging-related indications Plan to initiate Phase 1b/2a study in Parkinson's disease in 1Q19 Building a pipeline targeting multiple mechanisms underlying the biology of aging Significant market opportunity due to the rapidly growing

aging population and the potential of TORC1 inhibition to improve the function of multiple aging organ systems QD = once daily; RTI = respiratory tract infection

Aging is the biggest risk factor for

most chronic diseases Why does this happen? Aging is not just due to random wear and tear Aging is biology that may be targeted with medicines Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2017 (GBD 2017)

The TORC1 pathway Source: Lamming,

Dudley W., et al. (2013) Journal of Clinical Investigation123 (3): 980-989. TORC1 inhibition has extended lifespan and healthspan in multiple preclinical species Mice Flies Worms Yeast TORC1 is an evolutionarily conserved pathway that

Species Genetic Manipulation to Inhibit

mTOR Yeast SCH9 (Akt/S6K homolog) insertional mutant 1 SCH9 (Akt/S6K homolog) deletion 1 SCH9 (Akt/S6K homolog) insertional mutant 2 SCH9 (Akt/S6K homolog) deletion 2 TOR1 deletion 3 TOR1 deletion 4 C. elegans TOR (let-363) RNAi 5 Raptor (daf-15)

heterozygous 6 S6K (rsks-1) RNAi 7 S6K (rsks-1) deletion mutant 7 TOR (let-363) RNAi 7 S6K (rsks-1) RNAi 8 S6K (rsks-1) deletion mutant 8 TOR (let-363) RNAi 8 Raptor (daf-15) RNAi 9 RagGTPase (raga-1) RNAi 9 RagGTPase (raga-1) RNAi 9 Rheb (rheb-1)

RNAi 9 D. melanogaster dTSC1 overexpression 10 dTSC2 overexpression 10 dTOR FRB domain (dominant negative) 10 dS6K dominant negative 10 DTOR mutant (hypomorph) 11 d4E-BP overexpression 12 d4E-BP weak activated 12 d4E-BP strong activated 12 M.

musculus Loss of S6K1 13 Mtor+/-MIst8+/- genotype 14 Extensive genetic validation that TORC1 inhibition extends lifespan across species Corresponding citations can be found on slide 40

TORC1 inhibitors extended lifespan in

mice even when started late in life and given intermittently Daily Dosing Intermittent Dosing Once Every 5 Days Harrison et al. (2009) Nature, 460:392-396 Arriola Apelo et al. (2016) Gerontol A Biol Sci Med Sci, 71: 876-88

TORC1 may become dysregulated and

overactive in some aging organ systems TORC1 activity (pS6 in liver) Fed Fasted Young Mice Old Mice Decreasing TORC1 activity may upregulate protective pathways and may have benefits in aging-related diseases Fed Fasted Total S6 Feeding activated

TORC1 leading to increased protein and lipid synthesis Fasting inhibited TORC1 leading to upregulation of protective pathways TORC1 activity remained aberrantly elevated during fasting , preventing upregulation of protective pathways Sengupta et

Inhibition of TORC1 has the potential

to improve the function of multiple aging organ systems Improvement in physical activity Selman et al., Science, 2011 Harrison et al., Nature, 2009 Wilkinson et al., Aging Cell, 2014 Flynn et al., Aging Cell, 2013 Reversal of aging-related immune

dysregulation Chen et al., Science Sig, 2009 Selman et al., Science, 2011 Neff et al., JCI, 2013 Hurez et al., Aging Cell, 2015 Reversal of aging-related cardiac dysfunction Flynn et al., Aging Cell, 2013 Dai et al., Aging Cell, 2014 Chiao et al.,

Aging, 2016 Improved neurologic function Tain et al., Nature Neuroscience, 2009 Malagelada et al., J Neurosci, 2010 Spilman et al., PLoS ONE, 2010 Halloran et al., Neuroscience, 2012 Majumder et al., Aging Cell, 2012 Neff et al., JCI, 2013

mTOR Selective inhibition of TORC1

may have therapeutic benefit for the treatment of aging-related diseases Inhibition of TORC2 by genetic mutation decreased lifespan and caused hyperglycemia and hyperlipidemia in mice (Science, 2012; Aging Cell, 2014) S6K Ulk1 4EBP1 Atg Inhibition

of TORC1 by genetic mutation extended lifespan (Science, 2012) Knock out of S6K extended lifespan and healthspan (Science, 2009) Overexpression extended lifespan (Cell, 2009) Transgenic overexpression extended lifespan (Nat Comm, 2013) TORC2 TORC1

S6K Ulk1 TORC1 everolimus or

sirolimus 4EBP1 S6K Ulk1 4EBP1 TORC1 RTB101 + everolimus or sirolimus 4EBP1 S6K Ulk1 TORC1 4EBP1 RTB101 Inhibits the phosphorylation of 1 target of TORC1 Inhibits the phosphorylation of 2 targets of TORC1 Inhibits the phosphorylation of 3 targets of

TORC1 Spectrum of TORC1 inhibition with RTB101 and rapalog = indicates phosphorylation is inhibited Nyfeler B, et al. Molecular and Cellular Biology, July 2011, p. 2867-2876; Nyfeler B, et al. (2012) PLoS ONE 7(11): e48548

Objective: Improve immune function

to decrease the burden of respiratory illness in the elderly

Results of Phase 2a trial 264 mostly

healthy elderly people randomized to the following TORC1 inhibitor treatment arms (all doses were QD): Both RTB101 10mg QD and RTB101 10mg + everolimus 0.1mg QD significantly reduced the incidence of all infections as well as respiratory tract

infections (RTIs) Reduction in RTIs: RTB101 10mg: 42% reduction (**p=0.006) RTB101 10mg + everolimus 0.1mg: 36% reduction (*p=0.01) Both RTB101 10mg and RTB101 10mg + everolimus 0.1mg upregulated antiviral gene expression in whole blood TORC1

inhibition QD = once daily; *p<0.05; **p<0.01; Statistically significant defined as a nominal p-value < 0.05 Everolimus 0.1mg + RTB101 10mg RTB101 10mg Everolimus 0.5mg Everolimus 0.1mg Placebo

RTB101: IMMUNOTHERAPY TARGETING

TORC1 RTB101 offers a potential new approach to harnessing the immune system to target multiple pathogens Source: S. Jain et al., NEJM 2015 Indicates the annual number of pathogen-specific pneumonia hospitalizations per 10,000 adults 80 The

majority of pathogens detected in elderly people hospitalized for pneumonia are viruses for which NO APPROVED THERAPIES are currently available Viruses with no FDA-approved therapies available * Incidence per 10,000 Persons 5 10 20 15 0 *Adenovirus

L. pneumophila S. aureus M. pneumoniae *Coronavirus *Respiratory Syncytial Virus *Parainfluenza Virus *Human Meta-Pneumovirus S. Pneumoniae Influenza A or B *Human Rhinovirus

Phase 2a to Phase 2b: Population,

primary endpoint and dosing duration were modified Self-reported RTIs Laboratory-Confirmed RTIs 6 weeks 16 weeks Healthy, 65 and older POPULATION: PRIMARY ENDPOINT: DOSING DURATION: Phase 2a Phase 2b Goal: Define patient population and dose for

Phase 2b design Primary Endpoint:

Reduction in the percentage of patients with laboratory-confirmed RTIs through week 16 Population: Elderly subjects at increased risk of RTI-associated morbidity and mortality, defined as: 85 years of age 65-84 years of age with one or more

comorbidities including: Asthma Chronic obstructive pulmonary disease (COPD) Type 2 diabetes mellitus (T2DM) Current smoker 16 weeks 8 weeks RTB101 5mg QD RTB101 10mg QD Placebo Follow-up Northern Hemisphere (n=473) RTB101 10mg + everolimus 0.1 mg

QD RTB101 10mg QD Placebo 16 weeks 8 weeks Follow-up RTB101 10mg BID Southern Hemisphere (n=179) QD = once daily; BID = twice daily Interim Analysis

Dosing regimens in Phase 2b

estimated to result in different duration and spectrum of TORC1 inhibition S6K Ulk1 4EBP1 TORC1 4EBP1 RTB101 5mg QD Intermittent inhibition of two TORC1 targets RTB101 10mg QD 0 12 24 Estimated duration of TORC1 inhibition (hrs) RTB101 10mg BID

Persistent inhibition of two TORC1 targets RTB101 10mg + everolimus 0.1mg QD Persistent inhibition of three TORC1 targets 0 12 24 0 12 24 QD = once daily; BID = twice daily

RTB101 10mg QD was observed to

reduce the incidence of laboratory-confirmed RTIs 21/61 26/60 0.618 0.109 34/176 50/180 0.601 0.025* 25/120 24/120 1.050 0.560 25/115 24/120 1.187 0.700 Active incidence1 Placebo incidence1 Odds ratio2 p-value3 1No. of subjects in cohort with one or

more laboratory-confirmed RTIs/No. of subjects in cohort; 2Odds ratio represents the odds of experiencing one or more laboratory-confirmed RTIs in the active treatment group versus the placebo group; 3One-sided p-value; *p<0.05; QD = once daily;

BID = twice daily Odds ratio (90% confidence interval) Odds ratio of experiencing lab-confirmed RTIs through Week 16 RTB101 5mg QD RTB101 10mg QD RTB101 10mg BID RTB101 10mg + everolimus 0.1mg 0.5 RTB101 10mg QD demonstrated a 30.6% reduction in the

percentage of subjects with laboratory-confirmed RTIs compared to placebo

COPD and smokers were non-responding

subgroups (pre-specified analyses) 85+: % subjects with 1 or more laboratory-confirmed RTIs Asthma T2DM COPD Smokers 65+: % subjects with 1 or more laboratory-confirmed RTIs Southern Hemisphere Northern Hemisphere Southern & Northern Hemispheres

(%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) -66.7% (p=0.052) -66.8% (p=0.053) -66.7% (**p=0.007) -68.1% (**p=0.001) -69.4% (*p=0.016) -68.9% (***p=0.0001) -40.5% (p=0.087) -15.4% (p=0.077) -25.3% (*p=0.028) 2.1% (p=0.168) 3.3%

(p=0.147) 410.7% (p=0.874) 0.0% (p=0.324) 201.2% (p=0.833) = placebo cohort; = RTB101 10mg once daily cohort; One-sided p-value; QD = once daily; BID = twice daily; *p<0.05, **p<0.01, ***p 0.001 311.9% (p=0.936)

In preclinical studies mTOR

inhibition decreased airway inflammation in asthma models and increased airway inflammation due to smoking Asthma Smoking mTOR inhibition with rapamycin (Rapa) significantly decreased airway inflammation in a preclinical asthma model in which mice

were exposed to intranasal house dust mites (HDM)1 Disruption of mTOR selectively in bronchial epithelial cells (mBE-mtor-/-) significantly increased cigarette smoke (CS)-induced lung inflammation in a COPD model in which mice were exposed to

cigarette smoke for 6 months2 1Mushaben E. M. et al., J Immunol 2011:187:5756-5763; 2 Wang Y et al., J Immunol 2018;200:2571-2580

A significant reduction in the

incidence of laboratory-confirmed RTIs was observed in subjects 65+ (excluding smokers/COPD subjects) 1No. of subjects in cohort with one or more laboratory-confirmed RTIs/No. of subjects in cohort; 2Odds ratio represents the odds of experiencing

one or more laboratory-confirmed RTIs in the active treatment group versus the placebo group; 3One-sided p-value; p<0.01; QD = once daily; BID = twice daily 15/41 21/42 0.510 0.0800 15/113 36/117 0.319 0.0007 14/83 15/75 0.786 0.2800 18/78

15/75 1.170 0.3500 Active incidence1 Placebo incidence1 Odds ratio2 p-value3 Odds ratio (90% confidence interval) Odds ratio of experiencing lab-confirmed RTIs through Week 16 RTB101 5mg QD RTB101 10mg QD RTB101 10mg BID RTB101 10mg + everolimus

End-of-Phase 2 meeting with FDA and

planned design of Phase 3 clinical trials Patient population: 65 and older excluding current smokers/COPD patients Dosing arms: RTB101 10mg QD vs. matching placebo Duration of treatment: 16 weeks during winter cold and flu season Primary endpoint:

Reduction in the percentage of subjects with clinical symptoms consistent with an RTI with or without laboratory-confirmation of a pathogen Expected safety database at NDA submission: 1,500 subjects Topline data expected mid-2020 FDA = U.S. Food and

Drug Administration; NDA = New Drug Application; QD = once daily; COPD = chronic obstructive pulmonary disease Important regulatory alignment for RTB101 Phase 3 program to support potential NDA submission

Planned design for Phase 3 clinical

trials Patient population: 65 and older excluding smokers/COPD subjects First Phase 3 Clinical Trial Second Phase 3 Clinical Trial 1:1 randomization n = 1,000 1:1 randomization n = 1,600 RTB101 10mg QD Matching placebo RTB101 10mg QD Matching

placebo Duration of treatment: 16 weeks during winter cold and flu season Duration of treatment: 16 weeks during winter cold and flu season Study 1 (planned initiation 2Q19) Study 2 (planned initiation 4Q19)

Planned primary and secondary

endpoints Primary endpoint: Reduction in the percentage of subjects with clinical symptoms consistent with an RTI with or without laboratory-confirmation of a pathogen Defined as clinically symptomatic respiratory illness Consistent with the Phase

2b clinical trial, the primary endpoint is based on prespecified diagnostic criteria that encompass multiple types of respiratory tract infections1 Secondary endpoint: Reduction in the percentage of subjects with clinically symptomatic respiratory

illness with laboratory-confirmation of a pathogen FDA alignment on primary endpoint that will evaluate RTB101's potential to reduce the incidence of multiple types of respiratory tract infections caused by multiple pathogens 1 Final eDiary

subject to FDA review

1No. of subjects in cohort with one